Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $107 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and maintained a $107 price target.
May 03, 2024 | 3:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed an Overweight rating on Ultragenyx Pharmaceutical with a $107 price target.
The reiteration of an Overweight rating by a reputable analyst firm like Cantor Fitzgerald, along with a significant price target of $107, suggests a positive outlook on Ultragenyx Pharmaceutical's stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90